CD19x22 CAR T / University of Colorado - LARVOL DELTA

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov) - P1 | N=53 | Recruiting | Sponsor: University of Colorado, Denver | N=26 ➔ 53

Enrollment change • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (ASH 2024) - P1/2 | "Pts with R/R LBCL and mantle cell lymphoma (MCL) who had received at least two lines of prior therapy were eligible and received a single infusion after a 3-days of fludarabine and cyclophosphamide lymphodepleting chemotherapy...CRS was managed with Tocilizumab and steroids...IEC-HS was treated with steroids, anakinra, and ruxolitinib...The trial is currently ongoing, and updated data will be presented at the meeting. This CAR is also being tested in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies and is reported separately (NCT05442515)"

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Large B Cell Lymphoma • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Rare Diseases • Solid Tumor • Thrombocytopenia • CD22

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: University of Colorado, Denver | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

New CAR T-Cell Trial Launched Through Gates Institute Packages Two CARs in One Treatment (University of Colorado Anschutz Medical Campus) - "A new phase 1 study of a chimeric antigen receptor (CAR) T-cell therapy at Children’s Hospital Colorado for pediatric patients with relapsed or refractory pre B-cell acute lymphoblastic leukemia (B-ALL) recently enrolled its first patient. The trial is the latest launched through Gates Institute, and is the fifth for which the Gates Biomanufacturing Facility produces the CAR T-cell product for research at the University of Colorado Anschutz Medical Campus...The first patient enrolled in the trial is a young adult who had relapsed several times after starting treatment for the disease as a teenager. (Patients from 3 months to 30 years of age are eligible for the trial.) He received the treatment in late October and has so far tolerated the treatment with the new CAR T cell well, says Fabrizio, who is a member of Gates Institute and the CU Cancer Center."

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov) - P1 | N=26 | Recruiting | Sponsor: University of Colorado, Denver | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD22

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov) - P1 | N=26 | Not yet recruiting | Sponsor: University of Colorado, Denver

CAR T-Cell Therapy • New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD22

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: University of Colorado, Denver | Active, not recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov) - P1 | N=3 | Active, not recruiting | Sponsor: University of Colorado, Denver | Recruiting ➔ Active, not recruiting | N=20 ➔ 3

CAR T-Cell Therapy • Enrollment change • Enrollment closed • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19